Browse > Article

A Randomized, Open Label, 2-Way Crossover Study to Assess the Pharmacokinetic Characteristics and Skin Irritation of Murupe$^{(R)}$ Patch Compared with Trast$^{(R)}$ Patch in Healthy Volunteers  

Choi, Yoon Jung (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
Kim, Young Mi (College of Pharmacy, Hanyang University)
Chung, Jae-Yong (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
Cho, Joo-Youn (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
Yu, Kyung-Sang (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
Jang, In-Jin (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
Lim, Kyoung Soo (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
Publication Information
Journal of Korean Society for Clinical Pharmacology and Therapeutics / v.21, no.1, 2013 , pp. 41-51 More about this Journal
Abstract
Background: A piroxicam patch has been widely used to treat musculoskeletal pain. The aim of this study was to assess the pharmacokinetic (PK) characteristics and skin irritation of Murupe$^{(R)}$ patch (piroxicam 96 mg) compared with Trast$^{(R)}$ patch (piroxicam 96 mg) in healthy volunteers. Methods: A randomized, open-label, 2-way crossover study was conducted in 12 healthy Korean male subjects. They were allocated to one of the two treatment sequences of RT and TR (R, reference drug, Trast patch; T, test drug, Murupe$^{(R)}$ patch). Each patch was applied to the subject once during 48 hours. Serial blood samples were collected up to 72 hours after removing the patch and plasma concentrations were determined by high performance liquid chromatography. Safety was monitored and the skin irritation potential was assessed. Results: The plasma concentration-time profile during 48 hours showed an exponential increase in both of two patch products. Mean $C_{max}$ and $AUC_{last}$ values were not statistically different between two patch groups. Mean $AUC_{[0-48h]}$ was lower in Murupe$^{(R)}$ patch group than that in Trast$^{(R)}$ patch group; 806.4 and $1196.5ng{\cdot}h/mL$. However, the mean $AUC_{[48-120h]}$ value tended to be higher in Murupe$^{(R)}$ patch group, implying more delayed excretion than in Trast$^{(R)}$ patch group; $2724.7ng{\cdot}h/mL$ and $1989.2ng{\cdot}h/mL$. The overall results of skin irritation potential test showed no clinically significant differences between two patch groups. Conclusion: Mean $C_{max}$ and $AUC_{last}$ values in Murupe$^{(R)}$ patch group were comparable to those in Trast$^{(R)}$ patch group. Murupe$^{(R)}$ patch was safe and well tolerated in healthy male subjects.
Keywords
Piroxicam patch; Pharmacokinetics; Skin irritation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Skjodt NM, Davies NM. Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. Clin Pharmacokinet, 1998;34(6):421-428.   DOI
2 Buckwalter JA, Mankin HJ. Articular cartilage: degeneration and osteoarthritis, repair, regeneration, and transplantation. Instr Course Lect, 1998;47:487-504.
3 Day RO, Brooks PM. Variations in response to non-steroidal anti-inflammatory drugs. Br J Clin Pharmacol, 1987;23(6):655-658.   DOI
4 Gennaro AR. Remington's Pharmaceutical Sciences. 18th ed, Mack Publishing Company, 1990;1116.
5 Bombardier C. An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol, 2002;89(6A):3D-9D.
6 Bijlsma JW, Patient benefit risk in arthritis-a rheumatologist's perspective. Rheumatology, 2010;49:ii11-ii17.   DOI
7 Derry S, Moore RA, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev, 2012;9:CD007400.
8 Dahl SL, Ward JR. Pharmacology, clinical efficacy, and adverse effects of piroxicam, a new nonsteroidal anti-inflammatory agent. Pharmacotherapy, 1982;2(2):80-90.   DOI
9 Fourtillan JB, Girault J. Piroxicam plasma concentrations following repeated topical application of a piroxicam 0.5 % gel. Drug Invest, 1992;4(5):435-440.   DOI
10 EMEA, EMEA web sites on PRESS RELEASE. Key expected results, http://www. ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500012655.pdf [Online] (last visited on 5 Feb 2013).
11 Allegrini A, Nuzzo L, Pavone D, Tavella- Scaringi A, Giangreco D, Bucci M, Toniato E, Mezzetti A, Martinotti S, Comuzio S, Di Grigoli M, Bonani S. Efficacy and safety of piroxicam patch versus piroxicam cream in patients with lumbar osteoarthritis. A randomized, placebo-controlled study. Arzneimittelforschung, 2009;59(8):403-409.
12 Campione E, Diluvio L, Paterno EJ, Chimenti S. Topical treatment of actinic keratoses with piroxicam 1 % gel: a preliminary open-label study utilizing a new clinical score. Am J Clin Dermatol, 2010;11(1):45-50.   DOI
13 Dixit M, Kini AG, Kulkarni PK. Preparation and characterization of microparticles of piroxicam by spray drying and spray chilling methods. Res Pharm Sci, 2010;5(2):89-97.
14 van Haselen RA, Fisher PA. A randomized controlled trial comparing topical piroxicam gel with a homeopathic gel in osteoarthritis of the knee. Rheumatology (Oxford), 2000;39(7):714-719.   DOI
15 Roy SD, Gutierrez M, Flynn GL, Cleary GW. Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design. J Pharm Sci, 1996;85(5):491-495.   DOI
16 KFDA, Korean Good Clinical Practice (KGCP), 2011.7.19 http://www.kfda.go.kr/ index.kfda?mid=95&seq=3566&cmd=v [Online] (last visited on 5 Feb 2013)
17 Cheong HA, Choi HK. Enhanced percutaneous absorption of piroxicam via salt formation with ethanolamines. Pharm Res. 2002;19(9):1375-1380.   DOI
18 Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basic for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vitro bioavailability. Pharm Res, 1995;12(3):413-420.   DOI
19 Dixit M, Kulkarni PK. Lyophilization monophase solution technique for improvement of the solubility and dissolution of piroxicam. Res Pharm Sci, 2012;7(1):13-21.
20 Lee JJ, Kim SY. Non-steroidal anti- inflammatory drug patch having improved penetration rate thereof by concentration gradient in matrix. patent registered, 10-2012-0054135 (2012)
21 Komatsu T, Sakurada T. Comparison of the efficacy and skin permeability of topical NSAID preparations used in Europe. Eur J Pharm Sci, 2012;47(5):890-895.   DOI
22 Hobbs DC. Pharmacokinetics of piroxicam in man. Eur J Rheumatol Inflamm, 1983;6(1):46-55.
23 Plessis JD, Stefaniak A, Eloff F, John S, Agner T, Chou TC, Nixon R, Steiner M, Franken A, Kudla I, Holness L. International guidelines for the in vivo assessment of skin properties in non-clinical settings: Part 2. Transepidermal water loss and skin hydration. Skin Res Technol, 2013 Jan 19. doi: 10.1111/srt.12037.